WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of AMGEN (AMGN)

Name AMGEN
Year low 47.66
Year High 70.00
Symbol AMGN
Last trade 69.28
Percentage change -0.49
Volume 6,595,401
Media Volume (3m) 8,646,300
PE Ratio 17.23
EPS 4.04
Market Cap 55147
Media fatt 15478
Trend fatt trend fatt graph for AMGEN
Media net income 3665
Trend net income trend net income for AMGEN
P / E P / E graph for AMGEN - 13 points 13
EPS EPS graph for AMGEN - 15 points 15
MARKET CAP / TOTAL REVENUE market cap / total revenue graph for AMGEN - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for AMGEN - 6 points 6
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for AMGEN - 0 points 0
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for AMGEN - 13 points 13
NET INCOME / MARKET CAP NET INCOME / MARKET CAP graph for AMGEN - 3 points 3
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for AMGEN - 6 points 6
NET INC1/NET INC3 net inc1/net inc3 graph for AMGEN - 0 points 0
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for AMGEN - 6 points 6
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for AMGEN - 5 points 5
. . graph for AMGEN - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for AMGEN - 1 points 1
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for AMGEN - 0 points 0
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for AMGEN - 0 points 0
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for AMGEN - 7 points 7
. . graph for AMGEN - 0 points 0
SELL HOLD BUY SELL HOLD BUY graph for AMGEN - 0 points 0
SINTESE 75

GRAPHS

max price logarithm graph for AMGEN based on no conditions max volume linear graph for AMGEN based on no conditions

News

Has Amgen Become the Perfect Stock? (Feb 02 - reuters) Noteworthy Insider Buys And Sells From Tuesday And Wednesday (Feb 01 - reuters) Which Big Biotech Is the Best Bet? (Jan 31 - reuters) 3 Biotech Stocks With A History Of Positive Earnings Surprises (Jan 30 - reuters) 5 Cash-Rich Income Plays (Jan 29 - reuters) Big Biotech Fuels M&A Activity (Jan 29 - reuters) Amgen's CEO Discusses Q4 2011 Results - Earnings Call Transcript (Jan 27 - reuters) Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33 (Jan 27 - reuters) Amgen to Acquire Micromet (Jan 26 - reuters) Amgen Acquires Micromet for $1.16 Billion (Jan 26 - reuters) Amgen to buy Micromet for over $1 billion (Jan 26 - reuters) Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results (Jan 25 - reuters) Current Trends In Cancer Therapeutic Development (Jan 24 - reuters) Critical Alerts for Amgen, Procter and Gamble, Suncor Energy, Under Armour, and Polycom Released by Seven Summits Research (Jan 24 - reuters) Amgen: Very Bullish But Protect New Investments (Jan 24 - reuters) JNJ Leads Field Of Healthcare Names Reporting Earnings This Week (Jan 23 - reuters) Amgen's 2012 Guidance On Tap (Jan 23 - reuters) Why Amgen Is Overvalued At $70 A Share (Jan 23 - reuters) 2 Medical Stocks to Buy, 3 to Avoid in 2012 (Jan 19 - reuters) Onyx Colon Cancer Drug Juggles Survival Benefit With Serious Side Effects (Jan 18 - reuters) 4 Biotech Stocks To Buy, 1 To Avoid (Jan 17 - reuters) TEVA's Neutroval: Are Biosimilars Coming To Antares Pharma? (Jan 17 - reuters) 30% Safe Upside For Merck, Amgen (Jan 12 - reuters) Amgen's Xgeva Prostate Indication Expansion Could be Blockbuster On Its Own (Jan 10 - reuters) Dako and Amgen to Collaborate in Development of a Companion Diagnostic for an Amgen Investigational Cancer Therapy (Jan 10 - reuters) Is Amgen's Stock Cheap by the Numbers? (Jan 08 - reuters) 12 Large-Cap Stocks Insiders And Short Sellers Are Dumping Like Crazy (Jan 06 - reuters) Will Amgen Buy Out Biogen Idec? (Jan 05 - reuters) Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference (Jan 05 - reuters) 5 Blue Chip Healthcare Stocks To Buy Now (Jan 03 - reuters) FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting (Dec 30 - reuters) Alnylam Looks Nearly Left For Dead (Dec 29 - reuters) 3 Investments That Crushed the Dow in 2011 (Dec 28 - reuters) 7 Covered Call Option Strategies For 2012 (Dec 28 - reuters) Biosimilars Could Increase Earnings For Drug Manufacturers (Dec 27 - reuters) These 6 Investments Just Got a Lot Better (Dec 22 - reuters) 4 Biotech Stocks With Consistently Rising EPS (Dec 22 - reuters) Monthly Income For January 2012 With Covered Call Trades (Dec 21 - reuters) Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs (Dec 20 - reuters) Valeant's Hostile Bid For ISTA (Dec 20 - reuters) Amgen,Watson to collaborate on cancer biosimilars (Dec 20 - reuters) Amgen, Watson to collaborate on cancer biosimilars (Dec 20 - reuters) Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars (Dec 19 - reuters) Cheap Large Cap Stocks To Own In 2012 (Dec 16 - reuters) 10 Best Mutual Funds of 2011 You've Never Heard Of (Dec 16 - reuters) Oncosec Looks to Zap Deadly Skin Cancer (Dec 16 - reuters) Amgen names new CEO, raises quarterly dividend (Dec 16 - reuters) Amgen Announces 2012 First Quarter Dividend (Dec 15 - reuters) Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 (Dec 15 - reuters) Amgen Announces Final Results of Its Tender Offer (Dec 14 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY